Thanks to the new XenoBase feature, users will now be able to directly search and interact with dose response curves and IC50 data for over 290 cell lines.
CrownBio will present new data on the development of preclinical solutions for NASH research, a therapeutic area with a high unmet need of models for pharmacological evaluation.
CrownBio’s ALL and AML patient-derived xenograft (PDX) models of different leukemia subtypes are unique in the commercial world, in that they are validated, stable models with typical leukemia symp...
OmniScreen™ will be run on a cycled schedule every three months, allowing clients to select from three panels of cell lines that are most suitable for their needs.
CrownBio has made the stable cell lines available for delivery, ready to be shipped overnight for next day delivery in the United States and within one week internationally.
Under the agreement, Progenics will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform™ for the development, manufacture, and commercialization of Progenics’ prostate specific...
Under the agreement, Liomont will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform for the development, manufacture and commercialization of an undisclosed antibody.
CrownBio offers a collection large enough to be representative of the histological and genetic diversity seen in the patient population in ongoing clinical trials.
19 of 24
Receive JSR Life Sciences news on your RSS reader.
